Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.2
Journals
JPM
Special Issues
Personalized Management of Inflammatory Bowel Diseases
share announcement

Personalized Management of Inflammatory Bowel Diseases

A Special Issue of Journal of Personalized Medicine (ISSN 2075-4426) belonging to the section "Personalized Therapy in Clinical Medicine".

Deadline for manuscript submissions: 30 June 2027 | Viewed by 1220

Editor

Dr. Tommaso Innocenti

E-Mail Website
Guest Editor
Gastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale G. B. Morgagni 50, 50134 Florence, Italy
Interests: gastroenterology; IBD; ultrasound; endoscopy

Special Issue Information

Dear Colleagues,

The management of inflammatory bowel disease (IBD) is undergoing a rapid transformation. The expanding armamentarium of advanced therapies underscores the urgent need to tailor treatment to the individual patient. A “one-size-fits-all” approach has dominated clinical practice in the past; however, over the last two decades, the concept of precision medicine has progressively emerged, first in oncology and later expanding towards other immune-mediated diseases. With molecular profiling, predictive biomarkers, and patient-level characteristics as its cornerstones, precision medicine has redefined therapeutic decision making shifting from empirical treatment algorithms to individualized strategies. In IBD, this approach is now gaining momentum, with predictive biomarkers, innovative diagnostic tools, and patient-specific disease trajectories increasingly guiding therapeutic decisions. As an example, while endoscopy has been the historical cornerstone for assessing disease activity and guiding management, the growing role of non-invasive techniques, particularly intestinal ultrasound (IUS), is reshaping disease monitoring, offering a patient-friendly and increasingly standardized approach.

This Special Issue aims to bring together cutting-edge research exploring biomarkers of response, novel imaging modalities, advanced endoscopic and histological assessments, and clinical strategies designed to foster individualized care. We welcome original articles and reviews that will help move IBD care toward truly personalized management.

Dr. Tommaso Innocenti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease
  • precision medicine
  • personalized management
  • biomarkers
  • intestinal ultrasound
  • advanced imaging
  • disease monitoring

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

21 pages, 779 KB  
Review
The Gut–Skin Axis in Atopic Dermatitis and Inflammatory Bowel Disease: Mechanisms, Microbiota, and Therapeutic Implications
by Ezzuddin Abuhussein, Edith V. Bowers, Yukihiro Yamaguchi, Keita Nishiyama, Olivia G. Cassidy, Koichi Tsuboi and Lei Huang
J. Pers. Med. 2026, 16(9), 482; https://doi.org/10.3390/jpm16090482 (registering DOI) - 18 Sep 2026
Abstract
The gut–skin axis is a bidirectional communication network linking the gastrointestinal tract, skin, microbiota, and immune system. As major barrier organs, the gut and skin harbor complex microbial communities that contribute to tissue homeostasis, immune regulation, and protection from environmental insults. Increasing evidence [...] Read more.
The gut–skin axis is a bidirectional communication network linking the gastrointestinal tract, skin, microbiota, and immune system. As major barrier organs, the gut and skin harbor complex microbial communities that contribute to tissue homeostasis, immune regulation, and protection from environmental insults. Increasing evidence indicates that dysbiosis of the gut and skin microbiota is associated with inflammatory diseases through interconnected microbial, metabolic, and immune pathways. Clinical observations further reveal strong associations between gastrointestinal disorders, including inflammatory bowel disease (IBD) and celiac disease, and cutaneous manifestations. Atopic dermatitis (AD) is characterized by epithelial barrier dysfunction, immune dysregulation, microbial imbalance, and environmental influences. Patients with AD frequently exhibit reduced gut microbial diversity, depletion of beneficial short-chain fatty acid (SCFA)-producing bacteria, and enrichment of potentially pathogenic microorganisms. Cutaneous dysbiosis, particularly expansion of Staphylococcus aureus, can further impair the skin barrier and sustain inflammation. Microbial metabolites, including SCFAs, tryptophan-derived aryl hydrocarbon receptor ligands, and bile acid metabolites, may mediate gut–skin communication by regulating epithelial integrity, immune tolerance, and inflammatory signaling. IBD is also increasingly recognized as a systemic disorder involving alterations in skin microbiota and cutaneous immunity. Intestinal inflammation may disrupt immune tolerance to skin commensals and promote cutaneous inflammation through cytokine signaling and immune-cell trafficking, while emerging evidence suggests reciprocal skin-to-gut effects. Epidemiologic, genetic, and clinical studies indicate an association between AD and IBD, potentially reflecting shared genetic susceptibility, barrier dysfunction, dysbiosis, and immune pathways. This review summarizes current evidence linking the gut–skin axis to AD and IBD. Full article
(This article belongs to the Special Issue Personalized Management of Inflammatory Bowel Diseases)
►▼ Show Figures

Figure 1

21 pages, 644 KB  
Review
Intestinal Ultrasound-Guided Precision Medicine in Inflammatory Bowel Diseases: A Narrative Review
by Cicerone Clelia, Fabrizio Fanizzi, Arianna Dal Buono, Ilaria Faggiani, Ferdinando D’Amico, Alessandra Zilli, Tommaso Lorenzo Parigi, Virginia Solitano, Federica Furfaro, Sara Massironi, Alessandro Armuzzi, Silvio Danese and Mariangela Allocca
J. Pers. Med. 2026, 16(7), 339; https://doi.org/10.3390/jpm16070339 - 23 Jun 2026
Viewed by 727
Abstract
Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are characterized by marked heterogeneity, challenging disease monitoring and individualized treatment. Despite advances in treat-to-target strategies, unmet needs persist, particularly in assessing transmural healing and optimizing therapeutic decisions. This narrative review evaluates the [...] Read more.
Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are characterized by marked heterogeneity, challenging disease monitoring and individualized treatment. Despite advances in treat-to-target strategies, unmet needs persist, particularly in assessing transmural healing and optimizing therapeutic decisions. This narrative review evaluates the role of intestinal ultrasound (IUS) as a key tool for precision medicine in IBD. IUS is a non-invasive, repeatable, and cost-effective imaging modality with diagnostic accuracy comparable to endoscopy and magnetic resonance enterography, with reported sensitivities and specificities frequently exceeding 80–90% for detecting active disease. It enables real-time assessment of transmural inflammation and complications, while parameters such as bowel wall thickness and Doppler vascularity support prognostic stratification. Early reductions in bowel wall thickness (≥25–30%) have been associated with improved treatment response, allowing identification of responders within weeks of therapy initiation. IUS informs therapeutic decision-making, including initiation, optimization, and de-escalation of advanced therapies, and may reduce reliance on invasive procedures. Integration into routine care has been associated with improved disease control and cost-effectiveness. Standardization of protocols, operator training, and prospective validation are required to establish IUS as a cornerstone of precision medicine in IBD. Full article
(This article belongs to the Special Issue Personalized Management of Inflammatory Bowel Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop